Alumis (ALMS) Non Operating Income (2023 - 2026)
Alumis (ALMS) posted quarterly Non Operating Income of $3.5 million for Q4 2025, down 9.03% year-over-year from $3.9 million in Q4 2024, and down 22.6% quarter-over-quarter from $4.5 million in Q3 2025.
Alumis (ALMS) Non Operating Income (2023 - 2026) Analysis & Trends
Alumis (ALMS) has reported Non Operating Income for 3 consecutive years, with $3.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non Operating Income fell 9.03% year-over-year to $3.5 million; the TTM figure through Dec 2025 stood at $201.9 million (up 2996.43% YoY), while the FY2025 annual figure was $201.9 million, up 2996.43% from the prior year.
- Non Operating Income fell to $3.5 million in Q4 2025 per ALMS's latest filing, from $4.5 million in the prior quarter.
- Across five years, Non Operating Income topped out at $191.3 million in Q2 2025 and bottomed at -$2.3 million in Q1 2024.
- Historically, Non Operating Income has averaged $19.2 million across 3 years, with a median of $2.6 million in 2025.
- Annual changes were most pronounced in 2024 — Non Operating Income sank 127.59% — and 2025, when it surged 52083.42%.
- Alumis' Non Operating Income stood at $832000.0 in 2023, then soared by 364.3% to $3.9 million in 2024, then fell by 9.03% to $3.5 million in 2025.
- Business Quant data shows ALMS's Non Operating Income at $3.5 million in Q4 2025, $4.5 million in Q3 2025, and $191.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Alumis | 3.25 Bn | 2.75 Bn | - | 4.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.88 Mn |
| Dec 31, 2025 | 3.51 Mn |
| Sep 30, 2025 | 4.54 Mn |
| Jun 30, 2025 | 191.30 Mn |
| Mar 31, 2025 | 2.57 Mn |
| Dec 31, 2024 | 3.86 Mn |
| Sep 30, 2024 | 5.28 Mn |
| Jun 30, 2024 | -368,000.00 |
| Mar 31, 2024 | -2.26 Mn |
| Dec 31, 2023 | 832,000.00 |
| Sep 30, 2023 | 382,000.00 |
| Jun 30, 2023 | 1.33 Mn |